drugset / Trial / NCT00027612

Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme

NCT00027612

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Irinotecan may make the tumor cells more sensitive to radiation therapy. PURPOSE: This phase I/II trial is studying the side effects of irinotecan given together with radiation therapy followed by irinotecan and carmustine and to see how well it works in treating patients with newly-diagnosed glioblastoma multiforme.

Timeline

Start
2002-07
Primary completion
2006-10
Completion
2009-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 75 mg/m2 Intravenous
Subject Irinotecan Small molecule 400 mg/m2 Intravenous
Subject carmustine Small molecule 100 mg/m2 Intravenous